- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06926790
NeoAdjuvant Nivolumab Plus ipilimumab в резекруемом NSCLC (Galaxy 3) (GALAXY 3)
Неоадъювантный ниволумаб плюс ипилимумаб при резекруемом немелкоклеточном раке легких
Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression <1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior responses in the treatment of advanced NSCLC. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Lung cancer remains the leading cause of cancer-related death globally. Neoadjuvant immunotherapy followed by surgery has been emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). Numerous clinical trials highlighted the efficacy of preoperative immunochemotherapy, including remarkably shrinking the primary lesion, eliminating micrometastases and ultimately contributing to survival outcomes. Notably, studies also demonstrated neoadjuvant immunochemotherapy increased the access of modified surgery and enhanced survival prognosis of patients with locally advanced NSCLC (IIIB).
Despite these advances, certain limitations remain. Conventional chemotherapy components may elevate treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1<1% remained to be improve. Emerging evidences demonstrated that nivolumab (anti-PD-1) combine with ipilimumab (antiCTLA-4) provided superior response for the treatment of advanced NSCLC patients. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC. The study will enroll 69 eligible participants, with the primary endpoint being pathological complete response (pCR) rate following neoadjuvant therapy.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
Контакты и местонахождение
Контакты исследования
- Имя: Shuben Li, Professor
- Номер телефона: 020-8306-2114
- Электронная почта: 13500030280@163.com
Места учебы
-
-
-
Guangzhou, Китай, 510120
- Рекрутинг
- First Affiliated Hospital of Guangzhou Medical University
-
Контакт:
- Shuben Li, PHD
- Номер телефона: +8613925810521
- Электронная почта: 13500030280@163.com
-
Контакт:
- Jiawei Chen, PHD
- Номер телефона: +8613925810521
- Электронная почта: m13925810521@163.com
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Informed consent must be signed.
- At least 18 years of age.
- Histologically or cytologically confirmed non-small cell lung cancer (without EGFR, ALK mutation).
- Have measurable and clinical stage II-IIIA with no known PD-L1 expression or PD-L1 ≤ 1%.
- disease eligible for surgery.
- No previous systematic therapy or radiotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- At least one measurable lesion.
- No major organ dysfunction, including liver, kidney, and cardiac function.
Exclusion Criteria:
- Patients with active autoimmune disease or history of autoimmune disease.
- Patients have received other treatment for non-small cell lung cancer or for any other malignancy.
- History of allergy to study drug components.
- Pregnant or breast-feeding.
- Any mental or psychological condition that would prevent the patient from completing the study or understanding the patient information.
- Patients who have other malignancies.
- History of major surgery or serious injury within the past 3 months.
- HIV, HBV, HCV infection or active pulmonary tuberculosis.
- Vaccination within 4 weeks prior to the start of the study.
- Presence of underlying medical conditions that, in the investigator's judgment, could increase the risk associated with study drug administration or interfere with the assessment of toxicity and adverse events.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Neoadjuvant treatment
Patients with IIA-IIIB NSCLC will received 2-3 cycles of neoadjuvant Nivolumab (3 mg/kg intravenously (i.v.), every 3 week) plus Ipilimumab (1 mg/kg i.v., every 6 week). Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy. After the second cycles treatment, contrast-enhanced chest CT will be performed to evaluate the tumor. |
This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Pathological Complete Response (PCR)
Временное ограничение: Within 2 weeks after surgery
|
Pathological complete response is predefined as no residual viable tumor cells in primary tumor and lymph nodes. |
Within 2 weeks after surgery
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
3-year Event-Free Survival (3-year EFS)
Временное ограничение: From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).
|
The starting point for EFS was the initiation of neoadjuvant treatment. The endpoint for EFS was defined as the date of death, recurrence, progression, or the last follow-up. |
From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).
|
|
Major Pathological Response (MPR)
Временное ограничение: Within 2 weeks after surgery
|
Major pathological response defined as less than 10% of viable tumor cells in primary tumor. |
Within 2 weeks after surgery
|
|
Safety (Rate of grade 3 and higher grade treatment-related adverse events (TRAEs))
Временное ограничение: Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)
|
Adverse events will be evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0). |
Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)
|
|
Radiological Response
Временное ограничение: Between the last dose of neoadjuvant treatment and surgery
|
Radiographic response will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. |
Between the last dose of neoadjuvant treatment and surgery
|
|
Postoperative complications
Временное ограничение: After the surgery assess to 90 days
|
Postoperative complications will be evaluated and recorded after the surgery following Clavien-Dindo grade. The minimum and maximum values were grade I-V, and the higher scores mean a worse outcomes. |
After the surgery assess to 90 days
|
|
Intraoperative bleeding
Временное ограничение: Up to approximately 20 weeks
|
Intraoperative bleeding was assessed and recorded by the surgical team. Blood loss was estimated by measuring suction canister volume and weighing surgical sponges, subtracting irrigation fluid. |
Up to approximately 20 weeks
|
|
The Quality of Life
Временное ограничение: From the Day 1 to at least 90 days after surgery
|
The quality of life will be evaluated and recorded according to the EORTC QLQ-C30. The minimum and maximum values were 0-100, and the higher scores mean a better outcome. |
From the Day 1 to at least 90 days after surgery
|
|
Duration of surgery
Временное ограничение: Up to approximately 20 weeks
|
Duration of surgery is the time spent in surgery. |
Up to approximately 20 weeks
|
|
Hospital Stay
Временное ограничение: Up to approximately 20 weeks
|
Hospital Stay is the length of inpatient time spent in hospital. |
Up to approximately 20 weeks
|
|
Feasibility (Completion rate of neoadjuvant treatment and surgery)
Временное ограничение: From date of treatment allocation until surgery, assessed up to 5 months
|
Propotion of patients who complete neoadjuvant treatment and receive surgery within 42 days after neoadjuvant treatment |
From date of treatment allocation until surgery, assessed up to 5 months
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Заболевания дыхательных путей
- Легочные заболевания
- Новообразования дыхательных путей
- Грудные новообразования
- Рак, Бронхогенный
- Бронхиальные новообразования
- Новообразования легких
- Карцинома немелкоклеточного легкого
- Аминокислоты, пептиды и белки
- Белки
- Антитела, моноклональные, гуманизированные
- Антитела, моноклональные
- Антитела
- Иммуноглобулины
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Ниволумаб
- Ипилимумаб
Другие идентификационные номера исследования
- ES-2025-027-01
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .